AI Engines For more Details: Perplexity Kagi Labs You
Vaginal Yeast Infection Treatment: Butoconazole nitrate is effective in treating vaginal yeast infections, also known as vulvovaginal candidiasis. It works by inhibiting the growth of Candida species, the fungi responsible for causing yeast infections.
Antifungal Activity: Butoconazole nitrate belongs to the azole class of antifungal agents. It works by interfering with the synthesis of ergosterol, a crucial component of fungal cell membranes. This disrupts the integrity of the fungal cell membrane, leading to cell death and elimination of the yeast infection.
Symptom Relief: Butoconazole nitrate helps relieve symptoms associated with vaginal yeast infections, including vaginal itching, burning, irritation, and abnormal vaginal discharge. It helps restore the normal balance of microorganisms in the vagina, alleviating discomfort and restoring vaginal health.
Single-Dose Treatment: Some formulations of butoconazole nitrate, such as Gynazole-1, offer a single-dose treatment regimen, which can be convenient for patients. This single-dose therapy provides effective relief of yeast infection symptoms with a reduced treatment duration compared to multi-day regimens.
Topical Application: Butoconazole nitrate is typically available as a vaginal cream, suppository, or ovule, which are administered topically into the vagina. This localized application allows for direct delivery of the medication to the site of infection, maximizing its efficacy and minimizing systemic side effects.
Convenience and Compliance: Butoconazole nitrate formulations offer convenience and ease of use for patients, allowing them to self-administer the medication at home. Compliance with treatment regimens is generally high due to the simplicity of administration and the rapid relief of symptoms.
Minimal Side Effects: Butoconazole nitrate is generally well-tolerated, and side effects are typically mild and transient. Common side effects may include vaginal burning, itching, irritation, or discomfort at the site of application. These side effects usually resolve on their own and do not require medical intervention.
Pregnancy and Lactation: Butoconazole nitrate may be used to treat vaginal yeast infections during pregnancy under the guidance of a healthcare professional. However, pregnant or breastfeeding individuals should consult their healthcare provider before using any medication to ensure safety for both the mother and the baby.
Avoidance of Sexual Activity: It is recommended to avoid sexual activity during treatment with butoconazole nitrate to prevent the spread of the infection to sexual partners and to avoid potential irritation or discomfort.
Recurrence Prevention: Butoconazole nitrate may help prevent recurrence of vaginal yeast infections in some cases by eliminating the underlying fungal infection. However, recurrent yeast infections may require additional measures such as lifestyle modifications or maintenance therapy to prevent future episodes.
Rank | Probiotic | Impact |
---|---|---|
species | Bifidobacterium longum | Reduces |
species | Escherichia coli | Reduces |
species | Lacticaseibacillus paracasei | Reduces |
subspecies | Bifidobacterium longum subsp. infantis | Reduces |
subspecies | Bifidobacterium longum subsp. longum | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
---|---|---|---|
Abdominal Aortic Aneurysm | 0 | 0 | |
Acne | 0 | 0 | |
ADHD | 3 | 1 | 2 |
Age-Related Macular Degeneration and Glaucoma | 1 | 0.5 | 1 |
Allergic Rhinitis (Hay Fever) | 2.7 | 0 | 0 |
Allergies | 5.3 | 2.5 | 1.12 |
Allergy to milk products | 1.9 | 0.7 | 1.71 |
Alopecia (Hair Loss) | 2.4 | 2.4 | |
Alzheimer's disease | 3.2 | 8 | -1.5 |
Amyotrophic lateral sclerosis (ALS) Motor Neuron | 3.2 | 0.9 | 2.56 |
Ankylosing spondylitis | 4.4 | 2.5 | 0.76 |
Anorexia Nervosa | 0.5 | 3.5 | -6 |
Antiphospholipid syndrome (APS) | 2.7 | 0 | 0 |
Asthma | 1.5 | 1 | 0.5 |
Atherosclerosis | 1 | 2 | -1 |
Atrial fibrillation | 4.3 | 2.2 | 0.95 |
Autism | 12 | 10 | 0.2 |
Barrett esophagus cancer | 0.3 | -0.3 | |
benign prostatic hyperplasia | 0.2 | 0.2 | |
Bipolar Disorder | 1.7 | 2 | -0.18 |
Brain Trauma | 0.5 | 1 | -1 |
Carcinoma | 4 | 3 | 0.33 |
Celiac Disease | 2.2 | 3 | -0.36 |
Cerebral Palsy | 0.8 | 2 | -1.5 |
Chronic Fatigue Syndrome | 6.7 | 7.8 | -0.16 |
Chronic Kidney Disease | 3.7 | 3 | 0.23 |
Chronic Lyme | 1 | -1 | |
Chronic Obstructive Pulmonary Disease (COPD) | 1.6 | 1.5 | 0.07 |
Chronic Urticaria (Hives) | 1.5 | 1.9 | -0.27 |
Coagulation / Micro clot triggering bacteria | 1.4 | 1.8 | -0.29 |
Colorectal Cancer | 4.5 | 1 | 3.5 |
Constipation | 2.2 | 1 | 1.2 |
Coronary artery disease | 2.5 | 1 | 1.5 |
COVID-19 | 11.8 | 16.7 | -0.42 |
Crohn's Disease | 8.6 | 7.4 | 0.16 |
cystic fibrosis | 0.6 | 1 | -0.67 |
deep vein thrombosis | 0.6 | 1.3 | -1.17 |
Depression | 10.3 | 10 | 0.03 |
Dermatomyositis | 0.3 | 0 | 0 |
Eczema | 1.2 | 2.7 | -1.25 |
Endometriosis | 3.4 | 1 | 2.4 |
Epilepsy | 2.9 | 2.4 | 0.21 |
Fibromyalgia | 4.5 | 4 | 0.13 |
Functional constipation / chronic idiopathic constipation | 6.1 | 4.9 | 0.24 |
gallstone disease (gsd) | 2.7 | 0.5 | 4.4 |
Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 1.9 | 1.3 | 0.46 |
Generalized anxiety disorder | 2.1 | 1.5 | 0.4 |
giant cell arteritis | 0.5 | -0.5 | |
Glioblastoma | 0.3 | -0.3 | |
Gout | 0.5 | -0.5 | |
Graves' disease | 1.5 | 2 | -0.33 |
Halitosis | 0.5 | 0.3 | 0.67 |
Hashimoto's thyroiditis | 3 | 0.5 | 5 |
Hidradenitis Suppurativa | 0.4 | 0.4 | |
Histamine Issues,Mast Cell Issue, DAO Insufficiency | 2.9 | 1.5 | 0.93 |
hypercholesterolemia (High Cholesterol) | 0.5 | 0.5 | |
hyperglycemia | 0.2 | 1.5 | -6.5 |
Hyperlipidemia (High Blood Fats) | 0.5 | 0.5 | 0 |
hypersomnia | 0.5 | -0.5 | |
hypertension (High Blood Pressure | 2.5 | 4.3 | -0.72 |
Hypothyroidism | 1.5 | -1.5 | |
Hypoxia | 1 | 1 | |
IgA nephropathy (IgAN) | 5.4 | -5.4 | |
Inflammatory Bowel Disease | 6.3 | 10.9 | -0.73 |
Insomnia | 1.3 | 1.5 | -0.15 |
Intelligence | 2 | 1 | 1 |
Intracranial aneurysms | 2 | 0.5 | 3 |
Irritable Bowel Syndrome | 3.5 | 4 | -0.14 |
Liver Cirrhosis | 4.6 | 3.3 | 0.39 |
Long COVID | 9.9 | 10 | -0.01 |
Low bone mineral density | 1.5 | -1.5 | |
Lung Cancer | 0.2 | 1.5 | -6.5 |
ME/CFS with IBS | 1.8 | 3.5 | -0.94 |
ME/CFS without IBS | 3.3 | 2.9 | 0.14 |
Menopause | 0 | 0 | |
Metabolic Syndrome | 8.9 | 8.3 | 0.07 |
Mood Disorders | 12.8 | 10.5 | 0.22 |
multiple chemical sensitivity [MCS] | 1.3 | 0.5 | 1.6 |
Multiple Sclerosis | 5.1 | 8.6 | -0.69 |
Multiple system atrophy (MSA) | 1.3 | 1 | 0.3 |
Neuropathy (all types) | 0.8 | 0.2 | 3 |
neuropsychiatric disorders (PANDAS, PANS) | 0.5 | 0.5 | |
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 3.5 | 4.5 | -0.29 |
NonCeliac Gluten Sensitivity | 0 | 0 | |
Obesity | 10.1 | 5.4 | 0.87 |
obsessive-compulsive disorder | 7.8 | 5.5 | 0.42 |
Osteoarthritis | 3.5 | 0.5 | 6 |
Osteoporosis | 2.2 | 1 | 1.2 |
pancreatic cancer | 0.3 | 0.3 | |
Parkinson's Disease | 2.8 | 5.5 | -0.96 |
Polycystic ovary syndrome | 3.7 | 2 | 0.85 |
Postural orthostatic tachycardia syndrome | 0.5 | 0.5 | 0 |
Premenstrual dysphoric disorder | 1 | 0.5 | 1 |
primary biliary cholangitis | 0.5 | 1.5 | -2 |
Psoriasis | 5.2 | 3.9 | 0.33 |
rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 8.5 | 3.9 | 1.18 |
Rosacea | 1.5 | 1 | 0.5 |
Schizophrenia | 6 | 2.5 | 1.4 |
scoliosis | 0.5 | 1.5 | -2 |
Sjögren syndrome | 2.5 | 3.5 | -0.4 |
Sleep Apnea | 1.5 | 2.5 | -0.67 |
Small Intestinal Bacterial Overgrowth (SIBO) | 0.7 | 0 | 0 |
Stress / posttraumatic stress disorder | 2.9 | 2.9 | 0 |
Systemic Lupus Erythematosus | 5 | 2 | 1.5 |
Tic Disorder | 1.5 | 2 | -0.33 |
Tourette syndrome | 0.5 | -0.5 | |
Type 1 Diabetes | 4.2 | 2.8 | 0.5 |
Type 2 Diabetes | 9.4 | 8.6 | 0.09 |
Ulcerative colitis | 3.4 | 5.5 | -0.62 |
Unhealthy Ageing | 7.2 | 2 | 2.6 |
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Explanations/Info/Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations. Please report any to us for correction.
Copyright 2016-2024 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 Β§β―1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.